They are the latest international trend: we are talking about GLP-1 Agonists drugs. In recent years, the spread of medications such as Ozempic and Wegovy has transformed GLP-1 receptor agonist drugs into one of the most discussed segments of the global pharmaceutical industry.
This is because molecules such as semaglutide, liraglutide and exenatide have expanded the role of metabolic therapy in the management of obesity and type 2 diabetes, shifting the focus from glycaemic control alone to the management of body weight and cardiovascular risk. At the same time, however, attention has also increased towards tolerability and the management of side effects, as well as towards the rebound risk following discontinuation of therapy.
But what are the main GLP-1 agonists and what differences exist between these molecules?
GLP-1 receptor agonists are drugs designed to mimic the action of glucagon-like peptide-1, an intestinal hormone involved in the regulation of blood glucose and appetite. After meals, natural GLP-1 stimulates insulin release, reduces glucagon secretion and contributes to the feeling of satiety.
The issue is that endogenous GLP-1 is degraded very rapidly by the DPP-4 enzyme. Pharmacological agonists, on the other hand, are developed to resist this degradation and maintain prolonged activity within the body.1
It is precisely this biological stability that has made possible the development of modern obesity and diabetes treatments based on GLP-1 agonists, also opening up new perspectives in reducing cardiovascular risk and metabolic management.
To truly understand how GLP-1 receptor agonists work, it is necessary to observe their effect on multiple metabolic levels simultaneously.
These drugs increase insulin secretion in a glucose-dependent manner, reduce glucagon and slow gastric emptying. At a central level, however, they act on the hypothalamic centres of satiety, contributing to appetite reduction and the so-called “food noise”.2
Essentially, the effect does not concern glycaemic control alone, because GLP-1 agonists modify eating behaviour and — consequently — caloric intake, which is why they are now also used in the chronic management of obesity.3
The main difference between natural GLP-1 and agonist drugs concerns the duration of biological action. As mentioned earlier, the peptide produced by the intestine is degraded within minutes by the DPP-4 enzyme, limiting its metabolic effect.
GLP-1 agonists, on the other hand, are designed to resist enzymatic degradation. This makes it possible to maintain active concentrations for much longer and to achieve significantly superior clinical effects on blood glucose control and weight loss.4
From a structural point of view, some agonists derive directly from analogues of human GLP-1, such as liraglutide and semaglutide. Others, such as exenatide, derive instead from exendin-4, a peptide isolated from the saliva of the Gila Monster lizard (a large venomous reptile belonging to the Helodermatidae family) and naturally more resistant to enzymatic degradation.
Over time, the class of GLP-1 agonists has evolved rapidly. The differences between one agonist and another concern duration of action, frequency of administration, effectiveness on weight reduction and tolerability.
Let us analyse three of the most widely used drugs.
Semaglutide represents one of the most advanced GLP-1 agonists currently available. The molecule has been designed to resist enzymatic degradation and maintain a half-life of approximately seven days, a characteristic that allows weekly administration.5
Marketed as Ozempic for type 2 diabetes and as Wegovy for the chronic management of obesity, semaglutide has redefined clinical expectations linked to metabolic drugs. The SELECT study (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), conducted on approximately 17,000 subjects with obesity or overweight, showed that semaglutide may help to reduce the risk of major cardiovascular events, such as stroke and heart attack. The data also highlighted a favourable impact on renal outcomes, with a reduction in the risk of death, significant worsening of renal function and the development of persistent microalbuminuria.6
Alongside its effectiveness, however, critical issues linked to tolerability have also emerged. Nausea, delayed gastric emptying, loss of muscle mass and management of rebound following discontinuation of therapy are pushing the sector towards more integrated models of metabolic and nutritional support.
Liraglutide was one of the first molecules in the class to consolidate the role of GLP-1 agonists in modern metabolic therapy. Unlike exenatide, it derives directly from a human GLP-1 analogue and presents structural modifications that prolong its duration of action.
The Victoza formulation is used in the treatment of type 2 diabetes, while Saxenda is indicated for the chronic management of obesity at different dosages. Administration takes place through daily subcutaneous injection. In addition to glycaemic control, liraglutide has shown significant cardiovascular benefits.
Despite the arrival of more recent molecules such as semaglutide and tirzepatide, liraglutide continues to represent an important reference point in the evolutionary history of this pharmacological class, especially for the role it played in expanding therapy towards the treatment of obesity.7
Exenatide was the first GLP-1 receptor agonist approved for the treatment of type 2 diabetes. The molecule derives from exendin-4, a peptide identified in the saliva of the Gila Monster, a North American lizard naturally equipped with a form more resistant to enzymatic degradation.
Unlike human analogues such as liraglutide and semaglutide, exenatide therefore belongs to the family of exendin-4 derivatives. The original Byetta formulation requires two daily subcutaneous administrations, generally before the main meals. A prolonged-release weekly version was later introduced.
From a clinical point of view, exenatide has demonstrated improvements in glycaemic control and promoted moderate weight loss. However, compared with more recent molecules, it presents lower effectiveness on weight reduction and less practical therapy management.8
Despite this, exenatide retains fundamental historical importance because it paved the way for the entire evolution of GLP-1 agonists now used in advanced metabolic management.
The effectiveness of GLP-1 agonists in weight loss and metabolic control has rapidly increased the spread of these therapies. At the same time, however, attention towards the side effects associated with treatment has also grown.
Gastrointestinal disorders represent the most common adverse reactions. Nausea, vomiting, diarrhoea, constipation and delayed gastric emptying occur especially during the initial stages of therapy or during dosage escalation.
Alongside gastrointestinal effects, scientific debate today is also focusing on more complex aspects such as loss of muscle mass, combined with reduced protein intake and the difficulty in maintaining results following discontinuation of therapy.
It is precisely in this context that new therapy support strategies are emerging. More and more companies are developing solutions aimed at managing gastrointestinal side effects, supporting muscle mass and maintaining metabolic continuity during and after GLP-1 treatment.
To respond to these needs, Cor.Con. International has developed solutions designed to support patients throughout the entire therapeutic journey. The focus concerns not only weight loss, but above all the quality of weight reduction, the sustainability of therapy and the management of rebound effects through an offering of supplements for GLP-1 side effects for every stage of treatment.
The choice of a GLP-1 agonist does not depend on a single parameter. One of the most relevant aspects concerns the main clinical objective. In patients with obesity or overweight, molecules such as semaglutide and tirzepatide have shown superior results in weight reduction compared with previous-generation agonists.
The frequency of administration also affects therapeutic choice. Weekly formulations often improve patient adherence compared with daily treatments, while oral formulations are opening new scenarios for those who refuse injectable therapy.
The presence of cardiovascular or renal comorbidities is another element to take into consideration. Several GLP-1 agonists have demonstrated broad benefits, not only on glycaemic control, because they contribute to reducing cardiovascular risk and improving overall metabolic protection.
Alongside effectiveness, however, it is becoming essential to evaluate therapy tolerability and sustainability. It is within this evolution that the supplements for the metabolic system developed by Cor.Con. International are positioned, aimed at metabolic and nutritional support in pathways linked to GLP-1 agonists and the management of side effects associated with therapy.
Understanding the role of GLP-1 agonists today therefore means looking not only at the drug itself, but at everything that revolves around the long-term clinical sustainability of weight loss.
References